Open-label, randomized, non-inferiority clinical trial of artesunate-amodiaquine versus artemether-lumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire

BACKGROUND: Emergence of artemisinin resistance has raised concerns that the most potent anti-malarial drug may be under threat. Artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AL) are, respectively, the first- and second-line treatments for uncomplicated falciparum malaria in Côte d’Ivo...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Malar J
मुख्य लेखकों: Toure, Offianan A, Assi, Serge B, N’Guessan, Tiacoh L, Adji, Gbessi E, Ako, Aristide B, Brou, Marie J, Ehouman, Marie F, Gnamien, Laeticia A, Coulibaly, M’Lanhoro AA, Coulibaly, Baba, Beourou, Sylvain, Bassinka, Issiaka, Soumahoro, Adama, Kadjo, Florence, Tano, Mea A
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2014
विषय:
Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4251865/
https://ncbi.nlm.nih.gov/pubmed/25409546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2875-13-439
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन